Hypertension is the most prevalent cardiovascular risk factor and carries the greatest population attributable risk for cardiovascular disease [1]. Better hypertension control is among the most effective public health and population healthcare levers for reducing years of life lost and disability adjusted life years [2]. Unfortunately, the global burden of hypertension and related cardiovascular and renal diseases continues to grow. Hypertension control rates remain low globally [3]. One relatively simple and potentially scalable approach to improving hypertension control is greater use of single-pill combinations (SPC) containing two or more different classes of antihypertensive medications as initial and add-in therapy [4–12].

In this editorial, the literature is selectively reviewed and summarised on SPC, especially as initial therapy, compared with monotherapy and multiple pill regimens on adherence, hypertension control, clinical outcomes, population impact and adverse effects. An attempt is made to quantify the relative use of SPC versus monotherapy and free-dose combinations in hypertension management. Barriers and potential pathways to greater use of SPC in managing hypertension are explored.

### Adherence

In a recent systematic review and meta-analysis, which included >370,000 individuals on SPC, adherence was significantly greater with SPC than free-equivalent combinations (FEC) in 18 of 23 studies, which included >250,000 individuals on SPC [11]. Most reports were from retrospective studies. Four studies showed non-statistically significant numerical advantages for SPC. In one cited report, SPC were associated with significantly greater adherence than FEC among both statin adherence and statin non-adherent subgroups, but adherence was significantly lower with SPC among statin naive individuals. The studies cited in the report, which provided data on adherence as the proportion of days covered or medication possession ratio, are summarised in Table 1. In general, SPC was associated with approximately a 10-percentage point (absolute 10%) higher adherence rate than FEC.

### BP reduction and hypertension control

Analyses of multiple randomised trials indicated that half-standard doses (one-quarter maximum recommended dose) of the major classes of antihypertensive medications lowered systolic (S)BP ~7 mmHg, standard doses ~9 mmHg and twice standard doses ~11 mmHg [12]. Consistent with these findings, a subsequent systematic review and meta-analysis [8] reported that two antihypertensive medication classes at 1/2-standard dose (one-quarter the maximum recommended dose) lowered SBP ~2.8 mmHg more than a single medication at standard dose. Two antihypertensive medications at standard dose lowered SBP ~7.5 mmHg more than a single medication at standard dose and increased the probability of controlling BP 42% (Risk Ratio 1.42 [95% confidence interval 1.27–1.58]) [8].

### Therapeutic inertia

A key challenge in clinical practice, unlike protocol-driven clinical trials conducted by trained investigative teams, is that individuals begun on monotherapy are more likely to remain on monotherapy than those begun on combination therapy, even after three years [6]. In the United States, available evidence indicate that the interval between follow-up visits for adults with uncontrolled hypertension occurs at an average interval of 14 weeks or nearly 3-1/2 months [13]. An antihypertensive medication class is added or the dose of an existing medication raised on roughly one in eight visits. Thus, it often takes two years or more of uncontrolled hypertension before antihypertensive medication is added or the dose increased for an existing medication. Similarly, in a report from Italy, 64% of individuals beginning with antihypertensive monotherapy remained on monotherapy three years later [7]. In contrast, 78% of adults initiated on combination therapy remained on combination therapy after three years. These observations align with evidence from clinical practice and clinical trials that initial treatment with SPC leads to greater reduction in BP and better hypertension control than initial monotherapy [4,5,8–10,14].

### Time to hypertension control

Not surprisingly, time to control is also more prompt with initial single-pill combination therapy than initial
monotherapy [4,5]. Time to control is an important variable as clinical outcomes are better when hypertension is controlled within the first three to six months of treatment than after longer periods of time [15].

**Anti-hypertensive efficacy of single-pill and free combinations that are not always equivalent classes**

Most SPC approved for clinical use have approximately additive antihypertensive effects [16]. By definition, SPC and FEC are equivalent medication classes. In clinical practice, a significant proportion of free combinations do not reflect any marketed SPC [5]. Moreover, a significant proportion of individuals on two antihypertensive medications, despite absence of compelling indications, report taking a combination of a renin-angiotensin system blocker and β-blocker [17], which have less than additive antihypertensive effects.

**Clinical outcomes**

As noted, adults with hypertension begun on a single antihypertensive medication often remain on a single medication for extended periods of time. Unfortunately, the majority of adults with hypertension are not controlled on monotherapy, even when maximally recommended doses are given [16]. Observational studies indicate that adults with hypertension who are initiated on a combination of two antihypertensive medication classes have fewer composite cardiovascular events than individuals initiated on monotherapy (Tables 2 and 3). Of interest, evidence also suggests that hard clinical outcomes including death are reduced when equivalent two-drug combination therapy is prescribed as a single-pill rather than as separate pills [18]. The difference appears to be driven by greater adherence as an on-treatment analysis did not show any significant difference in outcomes.

**Projected benefits of SPC vs. alternative therapeutic approaches**

The available data on SPC therapy and alternative treatment approaches to SPC including current treatment practices and free choice combinations were examined in a microsimulation model. The results suggested that the composite outcome of ischaemic heart disease, stroke and chronic kidney disease could be reduced across five countries ranging from a low of 4.9% to a high of 11.5% [19].

---

**Table 1.** Adherence with single-pill combinations compared to free-equivalent combinations.

| Study* Design     | SPC, N | FEC, N | **PDC SPC vs. FEC, p-value** |
|-------------------|--------|--------|------------------------------|
| Ah, et al         | RetroDB 20,175 | 20,175 | 80% vs. 70%, p < 0.01        |
| Breitscheidel, et al | RetroDB 45,511 | 26,172 | 78.1% vs. 71.5%, p < 0.0001 |
| Degli Esposti, et al | RetroCoh 302 | 791 | 79.8% vs. 70.9%, p < 0.01    |
| Dickson, et al     | RetroCoh 2336 | 3368 | 63.4% vs. 49%, p < 0.0001    |
| Hess, et al        | RetroCoh 7225 | 7224 | 76.3% vs. 54.4%, p < 0.0001  |
| Ho, et al          | RetroDB 13,176 | 4392 | 58% vs. 47%, p < 0.0001      |
| Hsu, et al         | RetroDB 5725 | 1623 | 42.1% vs. 32.4%, p < 0.0001  |
| Jin-Young, et al   | RetroDB 757 | 707 | MPR ≥ 80%: 91.9% vs. 88.9%, NS |
| Koval, et al       | RandPG 39 | 36 | 87% vs. 61%, p < 0.05        |
| Machniki, et al    | RetroDB 1884 | 1884 | 70.0% vs. 60.6%, p < 0.0001  |
| Marazzi, et al     | RanPro 154 | 152 | 94% vs. 85%, p = 0.034       |
| Schweizer, et al   | NRPro 197 | 138 | 100% vs. 92%, p = NS         |
| Tung, et al        | RetroDB 1136 | 4544 | PDC ≥ 80%: 65.0% vs. 56.9%, p < 0.001 |
| Yang, et al        | RetroDB 382,476 | 197,375 | 72.8% vs. 61.3% (11.6% [11.4–11.7]) |

*All studies in the table are from Parati, et al. [11].

†When only medication possess ratio (MPR) provided, MPR multiplied × 100 and expressed as percent to approximate proportion of days covered (PDC).

SPC: single-pill combinations; FEC: free equivalent combinations; RetroDB: retrospective database design; RetroCor: retrospective cohort; RetroOb: retrospective observational; RanPro: randomised, prospective; NRPro: non-randomised prospective; P = NS: not significant or not provided.

**Table 2.** Clinical outcomes with single-pill combinations versus comparators.

| Variable* | **Initial CombRx vs. MonoRx** | **Initial CombRx vs. MonoRx** | **SPC vs. FEC** |
|-----------|-------------------------------|-------------------------------|----------------|
| Primary Outcome | 0.84 (0.79–0.90), p < 0.0001 | 0.85 (0.74–0.97), p = 0.02 | 0.89 (0.81–0.97), p < 0.01 |
| Stroke/cerebrovascular disease | 0.85 (0.91–0.98), p = 0.027 | 0.83 (0.61–1.14), p = 0.26 | 1.08 (0.86–1.36, p = 0.51 |
| AMI/Ischaemic heart disease | 0.80 (0.71–0.91), p < 0.0001 | 0.73 (0.56–0.95), p = 0.02 | 0.89 (0.71–1.12), p = 0.33 |
| Heart Failure | 0.65 (0.51–0.82), p < 0.0001 | 0.90 (0.54–1.51), p = 0.69 | 0.93 (0.71–1.12), p = 0.62 |
| Death | 0.80 (0.72–0.89), p < 0.0001 | Not reported | 0.85 (0.77–0.94, p < 0.01 |

*Proportional Ratios and 95% confidence intervals adjusted for baseline covariates.

†Incidence Risk ratios [7] and Hazard Ratios [18] with 95% confidence intervals performed on high-density propensity score-matched groups.[7,18].

**CombiRx:** combination treatment with two anti-hypertensive medication either as a single-pill or separate pill; **SPC:** single-pill combination antihypertensive therapy; **FEC:** free equivalent combination single antihypertensive medication, two antihypertensive medications as two separate pills with same medications comparator SPC.
The burden of uncontrolled hypertension is very high, especially in low- and middle-income countries [1]. Scalable, low-complexity interventions including greater use of SPC emerge as important options for addressing the burden of preventable cardiovascular disease. A recently published analysis identified three key factors that impact the national uptake of SPC therapy for hypertension [20]. These items include: (i) inclusion of antihypertensive SPC on the national essential medications list (ii) recommended use of SPC in national or regional hypertension guidelines (iii) availability of SPC on the marketplace. The latter is unfortunately still a significant barrier for implementation, since there are significant regional differences regarding the availability of SPC. Indeed, although SPCs are widely available in some countries in Europe, North America (Canada and United States), and in Asia (China, Japan, India, and South Korea), fewer SPCs are available in countries in the Middle East and Australia, particularly those including a renin angiotensin system-blocker and a calcium channel blocker, while the corresponding information for Africa is in fact difficult to retrieve [10].

Concerns and limitations

In this editorial we have attempted to efficiently convey the advantages of SPC therapy as initial therapy for hypertension. Moreover, when patients require a third or occasionally a fourth medication to control hypertension, the use of SPC to reduce pill count appears advantageous. Nevertheless, a limited proportion of adults with hypertension can be controlled on standard or lower doses of a single antihypertensive medication class, which are often well tolerated. Many individuals controlled on monotherapy will be within 10 mmHg of their SBP goal before treatment. For these individuals, initiating treatment with a single medication class is appropriate [7,16]. Individuals who are older and frail also appear to be at greater risk for excessive reductions in BP [7]. For these individuals, initial monotherapy is appropriate. Another valid concern is that when adverse effects occur, it may be difficult to determine the responsible drug when starting with a SPC. Yet, evidence suggests that SPC therapy, especially at standard doses or lower, is well-tolerated with adverse effect and discontinuation rates that are not significantly different from those with standard or twice standard dose monotherapy and can be easily recognised [8].

Summary and recommendations

Potential, Pitfalls and Solutions.

Potential

Hypertension control is suboptimal globally and contributes to a devastatingly high health and economic burden of preventable cardiovascular and renal disease. Addressing the deficiency in hypertension control will require a multi-component approach. The extant literature indicates that greater use of SPC, especially as initial therapy, could substantially improve rates of hypertension control and decrease rates of cardiovascular disease and death.

Pitfalls

The majority of individuals with hypertension begins treatment with monotherapy, and unfortunately remain on monotherapy for an extended period of time, despite uncontrolled blood pressure. Several antihypertensive medications were among the top 300 medications prescribed in the U.S. during 2019. SPC accounted for 6.3% of antihypertensive medication prescriptions and 12.3% of antihypertensive medications within the top 300 (Table 3) [21].

| Top 300# | Med | Scripts | Pts | Top 300# | Med | Scripts | Pts |
|---------|-----|---------|-----|---------|-----|---------|-----|
| 3       | Lisinopril | 91.9 | 20 | 82 | Propranolol | 9.3 | 2.4 |
| 5       | Metoprolol | 74.6 | 15.2 | 99 | Hydralazine | 6.7 | 1.7 |
| 6       | Amlodipine | 73.5 | 16.4 | 115 | HCTZ/Triamterene | 5.8 | 1.3 |
| 9       | Losartan | 51.8 | 11.8 | 118 | Nifedipine | 5.6 | 1.2 |
| 11      | HCTZ | 38.6 | 9.4 | 130 | Benazepril | 5.3 | 1.3 |
| 17      | Furosemide | 28.4 | 6.6 | 135 | Chlorothalidone | 5.0 | 1.2 |
| 33      | Carvedilol | 20.6 | 4.6 | 140 | Guanfacine | 4.6 | 0.7 |
| 39      | Atenolol | 18.1 | 3.8 | 141 | Verapamil | 4.6 | 0.9 |
| 44      | HCTZ/Lisinopril | 16.0 | 3.3 | 154 | Valsartan | 4.2 | 1.1 |
| 63      | Spironolactone | 11.4 | 3.0 | 164 | Olmesartan | 3.7 | 1.0 |
| 64      | Clonidine | 11.4 | 2.2 | 170 | Prazosin | 3.6 | 0.6 |
| 72      | Diltiazem | 10.6 | 2.2 | 178 | Ramipril | 3.3 | 0.9 |
| 73      | HCTZ/Losartan | 10.3 | 2.3 | 181 | Irbesartan | 3.2 | 0.9 |

#Ranking number
Number of prescription (Scripts) and patients (Pts) in millions.

Variables impacting uptake of SPC across low- and middle-income countries

The burden of uncontrolled hypertension is very high, especially in low- and middle-income countries [1]. Scalable, low-complexity interventions including greater use of SPC emerge as important options for addressing the burden of preventable cardiovascular disease. A recently published analysis identified three key factors that impact the national uptake of SPC therapy for hypertension [20]. These items include: (i) inclusion of antihypertensive SPC on the national essential medications list (ii) recommended use of SPC in national or regional hypertension guidelines (iii) availability of SPC on the marketplace. The latter is unfortunately still a significant barrier for implementation, since there are significant regional differences regarding the availability of SPC. Indeed, although SPCs are widely available in some countries in Europe, North America (Canada and United States), and in Asia (China, Japan, India, and South Korea), fewer SPCs are available in countries in the Middle East and Australia, particularly those including a renin angiotensin system-blocker and a calcium channel blocker, while the corresponding information for Africa is in fact difficult to retrieve [10].
Therapy will occur at scale. The likelihood is low that this ideal scenario for initial monotherapy with add-on pills. Few would disagree with this premise, yet the likelihood is low that this ideal scenario for initial monotherapy will occur at scale.

Solutions
Evidence suggests that inclusion of antihypertensive SPCs on national formularies, recommendations for use of SPC in national hypertension guidelines, and ready availability and affordability of SPC in the marketplace improve uptake of this treatment option. Implementation of treatment algorithms based on initial use of SPC combined with ongoing audit and feedback on adherence to the algorithm and hypertension control can lead to hypertension control rates consistently exceeding 80%. Fortunately, change is non-linear. Given the tension between poor hypertension control rates and the burden of preventable disability on one hand and the benefits of greater hypertension control on the other, SPC emerges as a scalable component of the solution. The tipping point for adoption could well be decades ahead of the slow rate of linear change to date.

Disclaimer
The comments and conclusions in this paper are those of the authors and do not necessarily represent the views of the American Medical Association.

Disclosure statement
None of the authors has any conflicts relevant to this editorial.

Funding
The author(s) reported there is no funding associated with the work featured in this article.

ORCID
Brent M. Egan http://orcid.org/0000-0002-1470-5875
Sverre E. Kjeldsen http://orcid.org/0000-0003-2389-0272
Krzysztof Narkiewicz http://orcid.org/0000-0001-5949-5018
Reinhold Kreutz http://orcid.org/0000-0002-4818-211X
Michel Burnier http://orcid.org/0000-0003-1283-8487

References
[1] Fuchs FD, Whelton PK. High blood pressure and cardiovascular disease. Hypertension. 2020;75(2):285–292.
[2] Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol. 2020;16(4):223–237.
[3] Frieden TR. The future of public health. N Engl J Med. 2015;373(18):1748–1754.
[4] Feldman RD, Zou GZ, Vandervoot MK, et al. A simplified approach to the treatment of uncomplicated hypertension: a cluster randomized, controlled trial. Hypertension. 2009;53(4):646–653.
[5] Egan BM, Bandyopadhyay D, Shaftman SR, et al. Initial monotherapy and combination therapy and hypertension control in the first year. Hypertension. 2012;59(6):1124–1131.
[6] Rea F, Corrao G, Merlino L, et al. Initial antihypertensive treatment strategies and therapeutic inertia. Hypertension. 2018;72(4):846–853.
[7] Mancia G, Rea F, Corrao G, et al. Two-drug combinations as first-step antihypertensive treatment. Circ Res. 2019;124(7):1113–1123.
[8] Salam A, Kanukula R, Atkins E, et al. Efficacy and safety of dual combination therapy of blood pressure-lowering drugs as initial treatment for hypertension: a systematic review and Meta-analysis of randomized controlled trials. J Hypertension. 2019;37(9):1768–1774.
[9] Tsioufis K, Kreutz R, Sykara G, et al. Impact of single-pill combination therapy on adherence, blood pressure control, and clinical outcomes: a rapid assessment of recent literature. J Hypertens. 2020;38(6):1016–1028.
[10] Persu A, Lopez-Sublet M, Algharabiy EAE, et al. Starting antihypertensive drug treatment with combination therapy: controversies in hypertension - pro side of the argument. Hypertension. 2021;77(3):800–805.
[11] Parati G, Kjeldsen S, Coca A, et al. Adherence to single-pill versus free-equivalent combination therapy in hypertension. Hypertension. 2021;77(2):692–705.
[12] Law MR, Wald NJ, Morris JK, et al. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ. 2003;326(7404):1427.
[13] Bellows BK, Ruiz-Negrón N, Bibbins-Domingo K, et al. Clinic-based strategies to reach United States million hearts 2022 blood pressure control goals. Circ Cardiovasc Qual Outcomes. 2019;12(6):e005624.
[14] Webster R, Salam A, de Silva HA, for the TRIUMPH Study Group, et al. Fixed low-dose triple combination anti-hypertensive medications vs usual care for blood pressure control in patients with mild to moderate hypertension in Sri Lanka: a randomized clinical trial. JAMA. 2018;320(6):566–579.
[15] Mariampillai JE, Eskas PA, Heimark S, et al. A case for less intensive blood pressure control: it matters to achieve target blood pressure early and sustained below 140/90 mmHg. Prog Cardiovas Dis. 2016;59(3):209–218.
[16] Williams B, Mancia G, Spiering W, et al. 2018 Practice guidelines for the management of arterial hypertension of the European society of cardiology and the European society of hypertension. Blood Press. 2018;27(6):314–340.
[17] Egan BM, Yang J, Rakotz MK, et al. Self-reported antihypertensive medication class and relationship to treatment guidelines. Hypertension. 2022;79(2):338–348.

[18] Verma AA, Khuu W, Tadrous M, et al. Fixed-dose combination antihypertensive medications, adherence, and clinical outcomes: a population-based retrospective cohort study. PLoS Med. 2018;15(6):e1002584.

[19] Borghi C, Wang J, Rodionov AV, et al. Projecting the long-term benefits of single pill combination therapy for patients with hypertension in five countries. Int J Cardiol Cardiovasc Risk Prev. 2021;10:200102.

[20] Bruyn E, Nguyen L, Schutte AE, et al. Implementing single-pill combination therapy for hypertension: a scoping review of key health system requirements in 30 low- and Middle-income countries. Glob Heart. 2022;17(1):6.

[21] ClinCalc DrugStats Database. The top 300 drugs of 2019. https://clincalc.com/DrugStats/Top300Drugs.aspx# (accessed 04 May 2022).

[22] Berlowitz DR, Ash AS, Hickey EC, et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med. 1998;339(27):1957–1963.

Brent M. Egan
American Medical Association, Greenville, SC, USA
brent.egan@ama-assn.org

Sverre E. Kjeldsen
Departments of Cardiology and Nephrology, University of Oslo, Ullevaal Hospital, Oslo, Norway

Krzysztof Narkiewicz
Department of Hypertension and Diabetology, Medical University of Gdansk, Gdansk, Poland

Reinhold Kreutz
Charité – Universitätsmedizin Berlin, Institute of Clinical Pharmacology and Toxicology, Berlin, Germany

Michel Burnier
Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland

Received 13 June 2022; accepted 23 June 2022

© 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.